Ernexa Therapeutics Inc. financial data

Symbol
ERNA on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 07 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 70.08 % -1.4%
Debt-to-equity 540 %
Return On Equity -1,949 % -7%
Return On Assets -305 % -1.6%
Operating Margin -2,693 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7,848,889 shares -84.7%
Common Stock, Shares, Outstanding 7,849,000 shares +45.1%
Entity Public Float 8,900,000 USD -8.2%
Common Stock, Value, Issued 39,000 USD +44.4%
Weighted Average Number of Shares Outstanding, Basic 8,226,000 shares +21.8%
Weighted Average Number of Shares Outstanding, Diluted 8,226,000 shares +21.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 582,000 USD
Cost of Revenue 96,000 USD
General and Administrative Expense 5,284,000 USD -66.9%
Operating Income (Loss) -9,921,000 USD +47.1%
Nonoperating Income (Expense) -8,391,000 USD +67.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -18,312,000 USD +59.2%
Income Tax Expense (Benefit) 28,000 USD +86.7%
Net Income (Loss) Attributable to Parent -18,340,000 USD +59.2%
Earnings Per Share, Basic 86 USD/shares +99.8%
Earnings Per Share, Diluted 86 USD/shares +99.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4,315,000 USD +66.9%
Assets, Current 3,379,000 USD -28.6%
Property, Plant and Equipment, Net 92,000 USD -12.4%
Operating Lease, Right-of-Use Asset 541,000 USD -24.8%
Goodwill 2,044,000 USD 0%
Other Assets, Noncurrent 116,000 USD -3.3%
Assets 6,172,000 USD -20%
Accounts Payable, Current 958,000 USD -56.3%
Employee-related Liabilities, Current 12,000 USD -88.9%
Accrued Liabilities, Current 859,000 USD -26.3%
Contract with Customer, Liability, Current 5,335,000 USD
Liabilities, Current 2,144,000 USD -78.5%
Operating Lease, Liability, Noncurrent 346,000 USD -35.2%
Other Liabilities, Noncurrent 112,000 USD +33.3%
Liabilities 2,602,000 USD -95.1%
Retained Earnings (Accumulated Deficit) -244,126,000 USD -8.1%
Stockholders' Equity Attributable to Parent 3,570,000 USD
Liabilities and Equity 6,172,000 USD -20%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2,065,000 USD +44.9%
Net Cash Provided by (Used in) Financing Activities 2,254,000 USD +62.7%
Net Cash Provided by (Used in) Investing Activities -97,000 USD
Common Stock, Shares Authorized 150,000,000 shares +50%
Common Stock, Shares, Issued 7,849,000 shares +45.1%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3,047,000 USD -28.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 26,023,000 USD +42.2%
Deferred Tax Assets, Gross 26,347,000 USD -10%
Operating Lease, Liability 552,000 USD -24.9%
Payments to Acquire Property, Plant, and Equipment 101,000 USD
Lessee, Operating Lease, Liability, to be Paid 625,000 USD -26.9%
Property, Plant and Equipment, Gross 257,000 USD -57.7%
Operating Lease, Liability, Current 206,000 USD +2.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 200,000 USD -25.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 304,000 USD +10.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure +19.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 73,000 USD -39.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 95,000 USD -41.7%
Preferred Stock, Shares Issued 156,000 shares 0%
Preferred Stock, Shares Authorized 1,000,000 shares 0%
Unrecognized Tax Benefits 393,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 82,000 USD -98.7%
Additional Paid in Capital 247,656,000 USD +37.3%
Preferred Stock, Shares Outstanding 156,000 shares 0%
Depreciation, Depletion and Amortization 18,000 USD -53.8%
Deferred Tax Assets, Net of Valuation Allowance 324,000 USD -97%
Share-based Payment Arrangement, Expense 1,573,000 USD +23.4%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%